Related Experiment Videos
Survival in systemic lupus erythematosus
M G Ridley1, P J Long, G R Hughes
1Lupus/Arthritis Research Unit, The Rayne Institute, St Thomas' Hospital, London.
British Journal of Hospital Medicine
|March 1, 1988
Summary
Systemic lupus erythematosus (SLE) prevalence is rising globally, with increased late cardiovascular disease linked to antiphospholipid antibodies. Infections remain a major cause of mortality in SLE patients despite conservative management.
Area of Science:
- Rheumatology
- Immunology
- Cardiovascular Disease
Background:
- Systemic lupus erythematosus (SLE) prevalence is increasing worldwide, partly due to identifying milder disease forms.
- While significant renal disease has become less common in SLE, late-onset cardiovascular disease is increasingly reported.
- Cardiovascular complications in SLE were historically attributed to steroid therapy, but thrombotic tendencies are now recognized.
Purpose of the Study:
- To analyze the changing patterns of morbidity and mortality in Systemic Lupus Erythematosus.
- To investigate the contribution of antiphospholipid antibodies to cardiovascular disease in SLE.
- To highlight the persistent threat of infection as a cause of mortality in SLE.
Main Methods:
- Review of epidemiological data on SLE prevalence.
- Analysis of clinical outcomes, focusing on renal and cardiovascular disease.
- Evaluation of mortality statistics in SLE patients.
Main Results:
- Increased global prevalence of SLE, including milder forms.
- Decreased incidence of significant renal disease.
- Higher reporting of late cardiovascular disease, with a suspected link to antiphospholipid antibodies.
- Infection remains a leading cause of mortality in SLE.
Conclusions:
- Antiphospholipid antibodies play a significant role in the increased cardiovascular risk in SLE patients.
- Despite treatment advancements, infection continues to be a major mortality factor in SLE.
- Understanding these evolving trends is crucial for managing SLE patients effectively.